Skip to search.
 TSX Down0.74% TSX Ventures 0.00%

Ligand Pharmaceuticals Incorporated (LGND)

-NasdaqGM

27.95 May 23, 4:00PM EDT

Add to Portfolio
Income StatementGet Income Statement for:
View: Annual Data | Quarterly DataAll numbers in thousands
Period Ending2013-03-302012-12-302012-09-292012-06-29
Total Revenue 11,651   13,635   6,375   5,742  
Cost of Revenue663  2,328  683  435  
Gross Profit 10,988   11,307   5,692   5,307  
Operating Expenses
Research Development2,465  2,475  2,647  2,851  
Selling General and Administrative4,502  4,284  4,382  4,026  
Non Recurring89  156  (14)86  
Others -   -   -   -  
Total Operating Expenses -   -   -   -  
Operating Income or Loss 3,932   4,392   (1,323) (1,656)
Income from Continuing Operations
Total Other Income/Expenses Net(1,650)(2,597)2,109  (1,413)
Earnings Before Interest And Taxes2,282  (1,510)786  (3,069)
Interest Expense912  (2,460)838  921  
Income Before Tax1,370  950  (52)(3,990)
Income Tax Expense66  (1,636)142  338  
Minority Interest -   -   -   -  
Net Income From Continuing Ops1,304  2,586  (194)(4,328)
Non-recurring Events
Discontinued Operations191  (1,523) -  1,799  
Extraordinary Items -   -   -   -  
Effect Of Accounting Changes -   -   -   -  
Other Items -   -   -   -  
Net Income 1,495   1,063   (194) (2,529)
Preferred Stock And Other Adjustments -   -   -   -  
Net Income Applicable To Common Shares 1,495   1,063   (194) (2,529)

Sign Up for a Free Trial to EDGAR Online Premium!
Get the critical business and financial information you need for more than 15,000 U.S. public companies.
Sign Up Now - Learn More

Currency in USD.